复方丹参注射液联合三维适形放疗同步化疗治疗局部晚期非小细胞肺癌  

Salvia Miltiorrhiza Injection combined with 3-D conformal radiotherapy and synchronous chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：刘仙明[1] 郭建平[1] 孙建刚[1] 周尔玺 王晓燕[1] 

机构地区：[1]山东省淄博市妇幼保健院肿瘤科,山东淄博255021

出　　处：《中国医药导报》2012年第22期99-101,共3页China Medical Herald

摘　　要：目的评价复方丹参注射液联合三维适形放疗(3DCRT)同步化疗治疗局部晚期非小细胞肺癌(NSCLC)的临床疗效和副作用。方法 92例局部晚期NSCLC患者分为两组,其中丹参组43例采用复方丹参注射液联合三维适形放疗同步化疗,对照组49例采用三维适形放疗同步化疗,化疗采用多西他赛+顺铂方案,化疗周期为6个周期。对两组临床疗效和不良反应进行评价。结果丹参组近期有效率为58.1%,中位生存期为18.25个月,对照组近期有效率为34.7%,中位生存期为13.93个月;丹参组放射性肺炎的发生率小于对照组,两组近期疗效和远期疗效差异均有统计学意义(P<0.05)。结论复方丹参注射液可以提高晚期NSCLC的临床疗效,并减少放射性肺炎的发生率。Objective To evaluate the efficacy and adverse reactions of local advanced non-small cell lung cancer （NSCLC） treated with Salvia Miltiorrhiza Injection combined with 3-D conformal radiotherapy and synchronous chemotherapy. Methods 92 patients with advanced NSCLC were divided into two groups, 43 cases of Salvia Miltiorrhiza group were treated with Salvia Miltiorrhiza combined with 3-D eonformal radiotherapy and synchronous chemotherapy. 49 cases of control group were treated with 3-D conformal radiotherapy and synchronous chemotherapy. The chemotherapy project was Docetaxel plus Cisplatin, All patients were given 6 periods. The two groups were evaluated the efficacy and adverse reactions. Results The short-term efficacy was 58.1% in the Salvia Mihiorrhiza group and 34.7% in the control group. The median survival time was 18.25 months in the Salvia Miltiorrhiza group and 13.93 months in the control group. There was more decreased incidence of radiation pneumonitis in Salvia Miltiorrhiza group than that in control group. There was significant difference in short-term and long-term efficacy between the two groups （P 〈 0.05）. Conclusion Salvia Mihiorrhiza can improve the efficacy of patients with advanced NSCLC, and decrease the incidence of radiation pneumonitis.

关 键 词：复方丹参注射液 三维适形放疗 同步化疗 非小细胞肺癌 放射性肺炎 

分 类 号：R734.2[医药卫生—肿瘤]